Copan Launches UriVerse™: Fully Automated Solution for Urine Specimen Aliquoting
Revolutionizing Urine Specimen Workflow
Urine specimens constitute a significant portion of the laboratory's daily workload, yet key pre-analytical steps like aliquoting are often still performed manually. UriVerse can reduce hands-on time, minimize errors, and help laboratories handle growing urine volumes with greater efficiency and consistency. UriVerse eliminates manual pipetting and sorting with continuous, random-access loading, cup recognition, and automated aliquoting, labeling and capping, all in one platform.
A Unique System for Urine Specimen Aliquoting
'Copan continues to pioneer technologies that support the advancement of laboratory automation,' said Fabrizio Mazzocchi, CEO of Copan Diagnostics. 'With UriVerse, we offer an efficient, accurate solution to help laboratories meet rising urine testing demands, particularly in chemistry and toxicology, while reducing variability through the automation of manual pre-analytical tasks.'
UriVerse is designed to address the challenges of modern urine testing workflows, especially in laboratories facing increasing volume, limited personnel, and rising expectations for faster turnaround time. By automating these manual processes, UriVerse supports better specimen traceability and fits easily into existing laboratory workflows.
UriVerse Now Available in the U.S.
Following its successful debut at ADLM, UriVerse is now available in the United States directly through Copan Diagnostics. The new instrument joins Copan's renowned portfolio of automation solutions, including WASP® and WASPLab®, reinforcing the company's commitment to innovation in specimen collection, transport, and pre-analytical automation.
About Copan Diagnostics, Inc.
Copan Diagnostics is part of Copan Group, a leading global manufacturer of collection and transport systems. Through its collaborative approach, Copan has developed breakthrough technologies such as FLOQSwabs®, ESwab®, UTM® Universal Transport Medium™, and full laboratory automation and artificial intelligence. Copan continues to innovate and transform collection and transport systems, as well as laboratory automation, assisting healthcare providers to improve patient care.
For more information, visit copanusa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Conformal Medical Closes $32 Million Series D Extension to Advance its Next-Generation Left Atrial Appendage Occlusion Technology
New partner reinforces confidence in the company's progress and future potential. NASHUA, N.H., Aug. 12, 2025 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, announced the successful closing of its Series D extension financing, with a new partner joining inside investors to raise a total of $32 million. The funds will support the enrollment of the company's ongoing CONFORM Pivotal Trial and fund key pre-commercialization initiatives for CLAAS® AcuFORM™ LAAO system. The CONFORM Pivotal Trial is the company's clinical trial evaluating the safety and efficacy of the CLAAS® System compared to other commercially available LAAO devices and will support U.S. Food and Drug Administration (FDA) pre-market approval. The CLAAS AcuFORM System is designed to seal the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib) to reduce the risk of stroke without the need for anticoagulants. 'We are pleased to have treated over 100 patients with the next-generation AcuFORM™ System, with impressive deliverability and safety performance to date,' said James Reinstein, President and CEO of Conformal Medical. 'We look forward to building upon this robust body of evidence to further validate our one-size strategy, and the promising experience from our GLACE trial, demonstrating successful use of ICE guidance as it would eliminate the need for general anesthesia and intubation for these procedures.' Conformal Medical's proprietary CLAAS AcuFORM technology features a foam-based architecture designed to conform to a broad range of LAA anatomies with only two sizes. The AcuFORM device may also accelerate the shift to ICE-guided LAAO closure due to simplified sizing and seal confirmation, thereby potentially eliminating the need for a procedural transesophageal echocardiogram and general anesthesia. This is a significant advancement with the potential to shift clinical practice to a single-operator procedure that is less invasive for patients. The company remains focused on completing the CONFORM and GLACE clinical trials to demonstrate its safety profile and ability to offer breakthrough solutions that address unmet clinical needs and transform the way Left Atrial Appendage Occlusion is treated. Piper Sandler acted as exclusive financial advisor, and Gunderson Dettmer acted as legal counsel to Conformal Medical in this transaction. About CONFORM Pivotal Trial The CONFORM Pivotal Trial is a prospective, multicenter, randomized controlled study evaluating the safety and efficacy of the Conformal CLAAS AcuFORM System compared to other commercially available left atrial appendage (LAA) devices. The trial plans to randomize approximately 1,600 patients at sites worldwide and is now >30% enrolled. It aims to generate pivotal data supporting next-generation stroke prevention therapies for individuals with non-valvular atrial fibrillation (AFib) who are seeking an alternative to long-term oral anticoagulation. For more information, visit About Conformal Medical Conformal Medical, Inc. is a medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology is intended to make left atrial appendage closure a same-day, single-operator procedure. For more information, visit CAUTION: Investigational Device. The CLAAS System is limited by Federal (or United States) law to investigational use.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Copan Launches UriVerse™: Fully Automated Solution for Urine Specimen Aliquoting
MURRIETA, Calif., Aug. 12, 2025 /PRNewswire/ — Copan, a leader in microbiology laboratory and automation innovations, proudly announced the official launch of UriVerse™ during the Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo in Chicago, IL. UriVerse is a state-of-the-art, fully automated system that transforms the pre-analytical handling of urine specimens by automating key manual steps. UriVerse automates critical steps including de-capping, barcode labeling, aliquoting, and re-capping which helps laboratories reduce manual labor and minimize errors. Revolutionizing Urine Specimen Workflow Urine specimens constitute a significant portion of the laboratory's daily workload, yet key pre-analytical steps like aliquoting are often still performed manually. UriVerse can reduce hands-on time, minimize errors, and help laboratories handle growing urine volumes with greater efficiency and consistency. UriVerse eliminates manual pipetting and sorting with continuous, random-access loading, cup recognition, and automated aliquoting, labeling and capping, all in one platform. A Unique System for Urine Specimen Aliquoting 'Copan continues to pioneer technologies that support the advancement of laboratory automation,' said Fabrizio Mazzocchi, CEO of Copan Diagnostics. 'With UriVerse, we offer an efficient, accurate solution to help laboratories meet rising urine testing demands, particularly in chemistry and toxicology, while reducing variability through the automation of manual pre-analytical tasks.' UriVerse is designed to address the challenges of modern urine testing workflows, especially in laboratories facing increasing volume, limited personnel, and rising expectations for faster turnaround time. By automating these manual processes, UriVerse supports better specimen traceability and fits easily into existing laboratory workflows. UriVerse Now Available in the U.S. Following its successful debut at ADLM, UriVerse is now available in the United States directly through Copan Diagnostics. The new instrument joins Copan's renowned portfolio of automation solutions, including WASP® and WASPLab®, reinforcing the company's commitment to innovation in specimen collection, transport, and pre-analytical automation. About Copan Diagnostics, Inc. Copan Diagnostics is part of Copan Group, a leading global manufacturer of collection and transport systems. Through its collaborative approach, Copan has developed breakthrough technologies such as FLOQSwabs®, ESwab®, UTM® Universal Transport Medium™, and full laboratory automation and artificial intelligence. Copan continues to innovate and transform collection and transport systems, as well as laboratory automation, assisting healthcare providers to improve patient care. For more information, visit
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Cineverse Technology Group's Flagship Brand Matchpoint™ Announces New Deals for its Proprietary Streaming Supply Chain Platform
LOS ANGELES, Aug. 12, 2025 /PRNewswire/ — Cineverse (Nasdaq: CNVS), a next-generation entertainment studio, has today announced that it has signed several new customers for Matchpoint™ — the industry-leading automated media supply chain platform that is radically changing the way video content is managed and delivered. This was announced today by Cineverse Technology Group's new EVP, Technology & General Manager of Matchpoint, Michele Edelman, who joined the Company this week in this newly-created role, following several months as a consultant. Among the new customers are a mix of studios and targeted streaming services that are using Matchpoint Dispatch – which helps launch and grow a streaming business via a fully-automated content management system, with asset ingest and delivery powered by trusted AI tools – and the scalable app building capabilities of Matchpoint Blueprint. Using both Blueprint and Dispatch are BeaconTV (true crime and paranormal), Elysium Media (positive reality and documentary) and Sweetspire TV (Where the South Tells its Stories). Additionally, producer and CEO Bob Yari's Magenta Light Studios (Bride Hard) is using Dispatch to distribute to digital platforms. Said Edelman, 'Whether looking to quickly stand up a new streaming app or channel that is ready for scale, or seeking AI powered tools for content ingest and delivery, analytics and insights, or to improve their search and discovery capabilities, platforms and media companies continue to look to Matchpoint to bring solutions to problems that would otherwise take major investments of time and capital to address on their own. We are proud of the market adoption we are seeing as we continue to execute on a very robust deal pipeline that shows strong market validation, and look forward to announcing more deals in the near future.' About Matchpoint™ Matchpoint™ is Cineverse's award-winning media supply chain platform that is radically changing the way content is managed and delivered. Matchpoint has replaced today's expensive, and labor-intensive video content processes with a fully transparent, automated workflow that significantly reduces costs, eliminates human error, and effortlessly facilitates content ingestion with delivery across multiple platforms and distribution models. About Cineverse Technology Group Cineverse develops proprietary technology that powers the future of entertainment, leveraging the Company's position as a pioneer in the video streaming industry along with the industry-leading strength of its development team in India. This team has dedicated years building and refining technology solutions that have pioneered streaming content management and distribution while leaning into advances in AI to set the company apart from the competition. This includes the creation of Matchpoint™, an award-winning media supply chain platform that is radically changing the way content is managed and delivered. The Company's cineSearch is an AI-powered search and discovery tool for film and television that makes deciding what to watch as entertaining as the entertainment itself. Additionally, the C360 programmatic audience network and ad-tech platform provides brands the opportunity to target and reach key fandoms wherever they are. About CineverseCineverse (Nasdaq: CNVS) is a next-generation entertainment studio that empowers creators and entertains fans with a wide breadth of content through the power of technology. It has developed a new blueprint for delivering entertainment experiences to passionate audiences and results for its partners with unprecedented efficiency, and distributes more than 71,000 premium films, series, and podcasts. Cineverse connects fans with bold, authentic, independent stories. Properties include the highest-grossing non-rated film in U.S. history; dozens of streaming fandom channels; a premier podcast network; top horror destination Bloody Disgusting; and more. Powering visionary storytelling with cutting-edge innovation, Cineverse's proprietary streaming tools and AI technology drive revenue and reach to redefine the next era of entertainment. For more information, visit CONTACTS For Media, The Lippin Group for Cineversecineverse@ For Investors, Julie Milsteadinvestorrelations@
